Renaissance Capital logo

Drugs Made In America Acquisition II Priced, Nasdaq: DMIIU

Blank check company targeting the pharmaceutical industry.

Industry: SPAC

Latest Trade: $10.03 0.00 (0.0%)

First Day Return: -0.1%

Return from IPO: +0.3%

Industry: SPAC

Drugs Made In America Acquisition II Corp. is a blank check company. While we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry. We have assembled a strong management team with a broad network of connections and corporate relationships across the pharmaceutical industry. We are confident that we will be able to use our individual experiences as well as our networks to achieve success. Together, we will formulate an all-encompassing plan for growth, one that accounts for both organic expansion and expansion via mergers and acquisitions. In the end, we will attempt to transform our target company into a widely respected industry leader by leveraging the benefits of becoming a public company, including access to finance and equity for expansion. At the same time, we will endeavor to generate excellent returns for our shareholders.
more less
IPO Data
IPO File Date 07/21/2025
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 50.0
Deal Size ($mm) $500
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 09/24/2025
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 50.0
Deal Size ($mm) $500
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Cantor Fitzgerald
Company Data
Headquarters Fort Lauderdale, FL, United States
Founded 2024
Employees at IPO 2

Drugs Made In America Acquisition II (DMIIU) Performance